phenoxybenzamine
|
|
phenoxybenzamine ??
- ???
- 38-40°
- ?? ?
- 381.5±27.0 °C(Predicted)
- ??
- 1.0513 (rough estimate)
- ???
- 1.5600 (estimate)
- ?? ?? (pKa)
- 6.58±0.50(Predicted)
- ??
- ?? ????? ???
- ????
- 0.176 W/(m·K)
- InChI
- InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3
- InChIKey
- QZVCTJOXCFMACW-UHFFFAOYSA-N
- SMILES
- C1(CN(CCCl)C(C)COC2=CC=CC=C2)=CC=CC=C1
- CAS ??????
- 59-96-1
??
| ?? ?? ??? | 59-96-1(Hazardous Substances Data) | ||
|---|---|---|---|
| ?? | LD50 oral in rat: 2500mg/kg |
phenoxybenzamine C??? ??, ??, ??
??
Antihypertensive.?? ??
Phenoxybenzamine has been the standard agent for blockade before adrenalectomy for pheochromocytoma. However, high cost and limited availability have hampered its use. Selective alpha blockers and calcium channel blockers are increasingly used[1].World Health Organization (WHO)
Phenoxybenzamine, a long-acting alpha-adrenoreceptor antagonist, was introduced in 1953 and has been used in a variety of peripheral vascular disorders. In 1982 it was shown to have mutagenic activity and in 1985 it was found to be carcinogenic in the rat. Its approved use was subsequently restricted by several regulatory authorities and phenoxybenzamine is currently used to manage hypertensive episodes associated with phaeochromocytoma, as an adjunct to the short-term management of urinary retention due to neurogenic bladder, in the short-term treatment of benign prostatic hypertrophy in patients awaiting surgery, and in inoperable benign prostatic hypertrophy.Safety Profile
Confirmed carcinogen with experimental carcinogenic and neoplastigenic data. Poison by intravenous and intracerebral routes. Moderately toxic by ingestion. Human reproductive effects by ingestion: spermatogenesis. Experimental reproductive effects. When heated to decomposition it emits very toxic fumes of Cland NOx.Purification Methods
The free base is crystallised from pet ether, and the HCl is crystallised from EtOH/diethyl ether. [Beilstein 12 IV 2204.]phenoxybenzamine ?? ?? ? ???
???
?? ??
phenoxybenzamine ?? ??
???( 28)?? ??
| ??? | ?? | ??? | ?? | ?? ? | ?? |
|---|---|---|---|---|---|
| Hinova Pharma | +86-18190684138 +86-18190684138 |
xhchen00241@hinovapharma.com | China | 61 | 58 |
| BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19936 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 |
marketing@targetmol.com | United States | 32468 | 58 |
| Shaanxi Dideu Medichem Co. Ltd | +86-29-81139210 +86-17392587031 |
1059@dideu.com | China | 9995 | 58 |
| Finetech Industry Limited | +86-27-8746-5837 +86-18627785180 |
info@finetechnology-ind.com | China | 9539 | 58 |
| Dayang Chem (Hangzhou) Co.,Ltd. | +86-0571-88938639 17705817739 |
info@dycnchem.com | China | 52704 | 58 |
| GIHI CHEMICALS CO.,LIMITED | +86-571-86217390; +8618058761490 |
info@gihichemicals.com | China | 49895 | 58 |
| Beijing HuaMeiHuLiBiological Chemical | 010-56205725 |
waley188@sohu.com | China | 12335 | 58 |
| Finetech Industry Limited | 027-87465837 19945049750 |
sales@finetechnology-ind.com | China | 9338 | 58 |
| Chengdu Saint - Kay Biotechnology Co., Ltd. | 028-85157043 15882256948 |
676046971@qq.com | China | 4191 | 58 |